The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2022 | The beneficial impact of CAR-T approvals for patients with R/R B-cell lymphoma
Nicholas Haradhvala, PhD, Broad Institute, Cambridge, MA, briefly discusses the impact that approvals in chimeric antigen receptor T-cell (CAR-T) therapy have had on patients with relapsed/refractory (R/R) B-cell lymphoma. Dr Haradhvala first mentions the promising effects that these therapies have for patients, and further discusses the potential for CAR-T to move up in therapy lines as the management of adverse events (AEs) and toxicities improves. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
